Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

About this update from Crinetics Pharmaceuticals, Inc.

SAN DIEGO , May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference , taking place June 3-5, 2025 in New York, NY . Jefferies Global Healthcare Conference 2025 Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern Time Webcast link: HERE The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events . If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations [email protected] (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075 Source: Crinetics Pharmaceuticals, Inc.

View stock analysis, news, and events for Crinetics Pharmaceuticals, Inc.